A recent phase 3 trial demonstrated a trend toward improved overall survival ( OS ) with decitabine , a hypomethylating agent , compared with treatment choice of either cytarabine or supportive care ( 7.7 months , 95 % CI : 6.2-9 .2 vs 5.0 months , 95 % CI : 4.3-6 .3 , respectively ) in older adults with newly diagnosed AML .